NEW YORK (360Dx) – Genomic Vision announced this week that it has received a second payment from Quest Diagnostics related to the companies' collaboration for the development of new biomarkers to improve the genetic detection of spinal muscular atrophy. The company declined to disclose the amount of the payment.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.